A Clinical Investigation Into the Association of an Impaired Skin Barrier and Infant and Toddler Sensitive Skin

NCT ID: NCT07225166

Last Updated: 2025-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-01

Study Completion Date

2025-11-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Single center, evaluator-blinded clinical trial that intends to • Evaluate differences in TEWL measurements between parent-reported sensitive skin subjects and healthy subjects (subjects without sensitive skin) • Evaluate differences in skin capacitance between parent-reported sensitive skin subjects and healthy subjects (subjects without sensitive skin). A sufficient number of subjects pairs (comprised of a parent subject and a child subject) will be enrolled to complete the study with at least 60 subject pairs (30 subject pairs per group).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sensitive Skin Non-sensitive Skin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-Sensitive Skin Group

* 5-8 babies that are 3 to 6 months old
* At least 5 babies that are 7 to 12 months old
* At least 10 toddlers that are 13 to 36 months old

Expert Clinical Grading

Intervention Type OTHER

The expert grader will separately assess each child subject's face and body (right and left volar forearms combined, right and left leg combined, torso) for each of the parameters below according to the following 4-point scales (half points are allowed):

\- Visual Dryness, Tactile Surface Roughness, Erythema.

Instrumental Measurements

Intervention Type OTHER

The following procedures will be conducted on the child subject:

* Corneometer measurements
* Tewameter measurements
* Skin pH Meter measurements

Parental Questionnaires

Intervention Type OTHER

The following questionnaires will be given to the parent subject to answer:

* Questionnaire: Reaction to Environmental, Chemical, and Mechanical Stimuli
* Questionnaire: Medical/Family History Questionnaire
* Questionnaire: Bathing and Skincare Routines

Biomarker Measurements

Intervention Type OTHER

The following procedures will be conducted on the child subject:

* D-Squame skin sampling (for corneocyte visualization and lipid analysis)
* Microbiome sampling
* D-Squame skin sampling (for inflammatory proteins)

Sensitive Skin Group

* 5-8 babies that are 3 to 6 months old
* At least 5 babies that are 7 to 12 months old
* At least 10 toddlers that are 13 to 36 months old

Expert Clinical Grading

Intervention Type OTHER

The expert grader will separately assess each child subject's face and body (right and left volar forearms combined, right and left leg combined, torso) for each of the parameters below according to the following 4-point scales (half points are allowed):

\- Visual Dryness, Tactile Surface Roughness, Erythema.

Instrumental Measurements

Intervention Type OTHER

The following procedures will be conducted on the child subject:

* Corneometer measurements
* Tewameter measurements
* Skin pH Meter measurements

Parental Questionnaires

Intervention Type OTHER

The following questionnaires will be given to the parent subject to answer:

* Questionnaire: Reaction to Environmental, Chemical, and Mechanical Stimuli
* Questionnaire: Medical/Family History Questionnaire
* Questionnaire: Bathing and Skincare Routines

Biomarker Measurements

Intervention Type OTHER

The following procedures will be conducted on the child subject:

* D-Squame skin sampling (for corneocyte visualization and lipid analysis)
* Microbiome sampling
* D-Squame skin sampling (for inflammatory proteins)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Expert Clinical Grading

The expert grader will separately assess each child subject's face and body (right and left volar forearms combined, right and left leg combined, torso) for each of the parameters below according to the following 4-point scales (half points are allowed):

\- Visual Dryness, Tactile Surface Roughness, Erythema.

Intervention Type OTHER

Instrumental Measurements

The following procedures will be conducted on the child subject:

* Corneometer measurements
* Tewameter measurements
* Skin pH Meter measurements

Intervention Type OTHER

Parental Questionnaires

The following questionnaires will be given to the parent subject to answer:

* Questionnaire: Reaction to Environmental, Chemical, and Mechanical Stimuli
* Questionnaire: Medical/Family History Questionnaire
* Questionnaire: Bathing and Skincare Routines

Intervention Type OTHER

Biomarker Measurements

The following procedures will be conducted on the child subject:

* D-Squame skin sampling (for corneocyte visualization and lipid analysis)
* Microbiome sampling
* D-Squame skin sampling (for inflammatory proteins)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Parent subject and child subject:

1. Generally, in good health based on medical history reported by the parent subject.
2. Intends to complete the study and is willing and able to follow the subject responsibilities and undergo necessary testing procedures (tape stripping for baby subjects) and answer multiple questionnaires.

Child subject:
3. Males and females aged 3 months-old up to 36 months-old (inclusive), targeting to complete with:

Sensitive Skin Cohort (cohort 1): at least 30 child subjects in the 3 months-old up to 36 months-old range with 100% HCP diagnosed sensitive skin or parent-reported sensitive skin, and as defined as parent subjects who respond "Yes" to the Yes/No question "Do you believe your child has sensitive skin?"

Non-Sensitive Skin Cohort (cohort 2): at least 30 child subjects in the 3 months-old up to 36 months-old age range with 100% having normal skin, has never been diagnosed with sensitive skin by a HCP, and as defined as parent subjects who respond "No" to the Yes/No question "Do you believe your child has sensitive skin?"
4. Has parent-reported natural skin tone "pale/fair to light white," "white to light beige," "beige to light tan/light olive," "medium tan/medium olive to light brown," "medium brown to dark brown," "darkest brown to darkest black", with every effort made to complete with at least 1 child subject for each skin tone per cohort.

Parent subject:
5. Is at least 18 years old.
6. Is the primary caregiver and legal guardian of the child subject and is willing and able to present proof of legal guardianship (e.g. birth certificate/hospital discharge paperwork along with valid ID of legal guardian, etc.).
7. Is able to read, write, speak, and understand English.
8. Has signed the Consent for Photo Release and ICD including a Health Insurance Portability and Accountability Act (HIPAA) disclosure.
9. Intends to complete the study and is willing and able to follow all study instructions.
10. Parent subjects must agree to discontinue child's current face/body washes and face/body lotions for 24 hours prior to their study visit.

Exclusion Criteria

Child Subject:

1. Is using Systemic or topical over-the-counter (OTC) or prescription medications that, in the Investigator's judgement, will affect skin condition or interfere with study evaluation. (Use of acetaminophen as needed is acceptable if it was instructed by the baby's pediatrician. Child vitamins are allowed.)
2. Is using topical steroids within 2 weeks before Visit 1.
3. Has Type 1 or Type 2 diabetes(reported by the parent) or is taking insulin or another anti-diabetic medication.
4. Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:

1. Immunosuppressive or steroidal drugs within 2 months before Visit 1
2. Non-steroidal anti-inflammatory drugs within 5 days before Visit 1
3. Antihistamines within 2 weeks before Visit 1
4. If an individual is taking one of these medication types, the individual is not considered eligible at screening. However, if a subject begins using one of these medications during the study, the Investigator should be consulted to consider the impact of the specific medication on subject safety and/or the study results.
5. Has a history of or a concurrent health/other condition/situation which may put the child subject at significant risk, confound the study results, or interfere significantly with the subject pair's participation in the study, as determined by the Investigator or designee.
6. Has a history of skin cancer.
7. Is simultaneously participating in another study involving product usage or skin sampling for the duration of the study or has participated in another study involving product usage or skin sampling within 14 days prior to Visit 1.
8. Has used new facial and body products and/or brands two weeks prior to Visit 1.
9. Is an immediate family member of the Investigator, Study Site, or Sponsor.
10. Presents with a skin condition that may confound the study results, increase risk to the subject, or influence the outcome of the study (e.g., psoriasis, eczema, atopic dermatitis, cutaneous xerosis, or active skin cancer), as determined by the Investigator or designee.

Parent subject:
11. Is simultaneously participating in another study.
12. Is an employee/contractor of the Study Site or Sponsor or immediate family member of the PI, Study Site, or Sponsor.
Minimum Eligible Age

3 Months

Maximum Eligible Age

36 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kenvue Brands LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

SGS North America, Inc. - Dallas Research Center

Richardson, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CS2025SK100263

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pre-SunBeam TEWL AUC
NCT04226092 COMPLETED NA
Bathing Babies and Allergy
NCT03050658 COMPLETED
Allergic Disease Onset Prevention Study
NCT05003804 COMPLETED PHASE1/PHASE2
Angioedema Biomarker Research Study
NCT06210698 NOT_YET_RECRUITING